20:35 EDT Cathie Wood’s ARK Investment buys 329K shares of Crispr Therapeutics (CRSP) today
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $79 from $80 at BofA
- Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations
- Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating
- Crispr Therapeutics upgraded to Buy from Hold at Clear Street
- Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating